CHANGE MY LOCATION
Business News
- Hurricane Ike damaged most of the homes on Grand Turk island as it roared onto the Bahamas, raked Haiti's flooded cities with rain and threatened the Florida Keys on its way to Cuba as a ferocious Category 4 storm Sunday.
- The House and Senate reconvene Monday after back-to-back political conventions, both parties eager to use the three-week session to show voters why their candidates are the ones to fix the economy and lower energy prices.
Candidates weigh in on stabilizing Fannie, Freddie- The historic takeover of Fannie Mae and Freddie Mac, which could come as soon as Sunday, moved to the forefront of the presidential campaign Saturday as candidates and congressional leaders seized on the enormous implications for taxpayers and the economy.
Pakistan suicide blast death toll reaches 35- The death toll in a massive suicide blast in Pakistan's militant-plagued northwest reached 35, officials said Sunday, as the country prepared for Benazir Bhutto's widower to take over as president.
- The banners, buttons and signs say McCain-Palin, but the crowds say something else.
- Five days a week, Linda Graham trolls tattered neighborhoods of this once thriving steel city outside Pittsburgh for unregistered voters she can sign up as Democrats - one of thousands of unknown volunteers whose work outside the limelight has already altered the basic arithmetic of the November election.
London calling at New York Fashion Week- Designers at New York Fashion week heard London calling - from 1975.
Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
SAN DIEGO
(Map)
-
Anadys will hold a conference call and webcast to discuss its second
quarter 2008 financial results and highlights and to provide an update on its
development programs on
About Anadys
Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing ANA598, a non-nucleoside polymerase inhibitor, and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include, but
are not limited to, references to Anadys' strategy, development programs, and
ability to develop novel medicines in the areas of hepatitis C and oncology.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause Anadys' actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. For example, the results of preclinical
studies may not be predictive of future results, and Anadys cannot provide any
assurances that ANA598 and ANA773 will not have unforeseen safety issues, will
have favorable results in future clinical trials or will receive regulatory
approval. Risk factors that may cause actual results to differ are discussed
in Anadys' SEC filings, including Anadys' Form 10-K for the year ended
|
|
